Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors-Reference-Cited by-同舟云学术

Antacid Use and De Novo Brain Metastases in Patients with Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Were Treated Using First-Line First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Published:2016-02-19 Issue:2 Volume:11 Page:e0149722
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Chen Yu-Mu,Lai Chien-Hao,Chang Huang-Chih,Chao Tung-Ying,Tseng Chia-Cheng,Fang Wen-Feng,Wang Chin-Chou,Chung Yu-Hsiu,Wang Yi-Hsi,Su Mao-Chang,Liu Shih-Feng,Huang Kuo-Tung,Chen Hung-Chen,Chang Ya-Chun,Lin Meng-Chih

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference22 articles.

1. Lung cancer incidence trends among men and women—United States, 2005–2009;SJ Henley;MMWR Morbidity and mortality weekly report,2014

2. Lung cancer and prognosis in taiwan: a population-based cancer registry;BY Wang;Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer,2013

3. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan;CH Lie;Clinical lung cancer,2011

4. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations;Y Kogure;PloS one,2015

5. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib;W Pao;Proceedings of the National Academy of Sciences of the United States of America,2004

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Drug-Drug Interactions Between Anti-Cancer Drugs and Other Medications in Lung Cancer Patients: A Retrospective Study;Current Drug Safety;2023-05

2. Evaluation of factors affecting epidermal growth factor receptor tyrosine kinase inhibitor-induced hepatotoxicity in Japanese patients with non-small cell lung cancer: a two-center retrospective study;Journal of Pharmaceutical Health Care and Sciences;2022-12-01

3. Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer;OncoTargets and Therapy;2022-12

4. The status of TKI/acid-suppressant concomitant use in 44 hospitals in China: A cross-sectional descriptive study;Medicine;2022-11-18

5. Impact of the Gastric Acid Suppressant Use on the Safety and Effectiveness of EGFR-TKIs: A Systematic Review and Meta-Analysis;Frontiers in Pharmacology;2022-06-20